Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale
Key Points
Johnson & Johnson generates consistently higher quarterly revenue than Bristol-Myers Squibb, maintaining a clear lead in total dollars over the entire observed eight-quarter period without any interruption.
Both companies experienced a gentle pattern of quarter-over-quarter revenue growth over the last two calendar years, though the exact quarterly figures occasionally fluctuated between consecutive reporting periods.
Investors should monitor whether the existing revenue gap between the two companies continues to gradually expand or begins to narrow during upcoming quarterly reporting cycles.
Bristol Myers Squibb: Slow and Steady Revenue Growth
Bristol Myers Squibb (NYSE:BMY) operates as a global biopharmaceutical entity that researches, develops, and commercializes a worldwide medicinal portfolio spanning therapeutic areas like hematology, oncology, and cardiovascular health, offering pharmaceutical products such as Revlimid and Eliquis.
It received accelerated regulatory approval from the U.S. Food and Drug Administration for its Zenbexus combination therapy for adult patients with multiple myeloma in August 2026, and it selected Houston for a new $2.3 billion multi-modal manufacturing campus designed to increase its production capacity for next-generation medicines.
Johnson & Johnson: Maintaining a Larger Revenue Base
Johnson & Johnson (NYSE:JNJ) functions as a broad healthcare holding company that engages in the research, development, manufacture, and global sale of products primarily through its dedicated innovative medicine and medical technology segments.
It finalized a $1 billion cash acquisition of Firefly Bio in July 2026 to integrate a targeted antibody-drug conjugate platform, while it also secured regulatory approval for its IMAAVY treatment for patients dealing with warm autoimmune hemolytic anemia.
Why Revenue Matters for Investors
Revenue here refers to the data provider's standardized income-statement revenue line item, which gives investors a direct baseline measurement of the total volume of money a business brings in from its core commercial operations before deducting any associated operating expenses, interest, or taxes.
Comparing Quarterly Revenue for Bristol Myers Squibb and Johnson & Johnson
| Calendar quarter | Bristol-Myers Squibb Revenue | Johnson & Johnson Revenue |
|---|---|---|
| Q3 2024 | $11.9 billion (quarter ended Sept. 30, 2024) | $22.5 billion (quarter ended Sept. 29, 2024) |
| Q4 2024 | $12.3 billion (quarter ended Dec. 31, 2024) | $22.5 billion (quarter ended Dec. 29, 2024) |
| Q1 2025 | $11.2 billion (quarter ended March 31, 2025) | $21.9 billion (quarter ended March 30, 2025) |
| Q2 2025 | $12.3 billion (quarter ended June 30, 2025) | $23.7 billion (quarter ended June 29, 2025) |
| Q3 2025 | $12.2 billion (quarter ended Sept. 30, 2025) | $24.0 billion (quarter ended Sept. 28, 2025) |
| Q4 2025 | $12.5 billion (quarter ended Dec. 31, 2025) | $24.6 billion (quarter ended Dec. 28, 2025) |
| Q1 2026 | $11.5 billion (quarter ended March 31, 2026) | $24.1 billion (quarter ended March 29, 2026) |
| Q2 2026 | $13.0 billion (quarter ended June 30, 2026) | $25.3 billion (quarter ended June 28, 2026) |
Data source: Financial Modeling Prep. Data as of Sept. 25, 2026.
Foolish Take
Both Bristol Myers Squibb and Johnson & Johnson are consistently, if slowly, growing their revenue, though Johnson & Johnson is obviously starting from a much larger base. In fact, despite Johnson & Johnson's revenue being about double that of Bristol Myers Squibb, over the period shown above, it grew its revenue at a slightly higher rate. That's impressive.
One thing to watch from here will be Johnson & Johnson's medical technology division, an area Bristol Myers Squibb, a biopharmaceuticals company, doesn't have. J&J's medtech division grew operational sales 3.6% in the second quarter, and in 2025, it generated $33.79 billion in revenue. It's growing the segment via both acquisitions and in-house research and development, which can be costly. However, once those products are approved and in use, they can generate exceptional revenue and high profit margins.
In July, J&J received FDA market authorization in the U.S. for its OTTAVA Robotic Surgical System, "the world's first table-integrated soft tissue robotic system." At the time of the announcement, a U.S. clinical trial for OTTAVA in inguinal hernia procedures was ongoing. Customer uptake and success with this system could provide a strong moat and a new recurring revenue stream for the legacy healthcare company.
Sarah Sidlow has positions in Johnson & Johnson. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.